Asteria Health recalled 62,581 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately and contact their healthcare provider for guidance. The recall affects testosterone pellets with specific lot numbers and expiration dates.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Testosterone, 87.5 mg, 1 Sterile Pellet, manufactured by Asteria Health. The affected lot numbers are 251000145, 251000161, and 251000175 with expiration dates of July 14, 2026, August 16, 2026, and September 8, 2026, respectively. The product was distributed nationwide in the USA.
The recall stems from the potential presence of metal particulate matter in the testosterone pellets. This contamination poses a serious health risk, as it can lead to severe injury or complications if ingested.
There have been no reported injuries or incidents related to this recall as of now. However, the potential for serious harm from metal contaminants necessitates immediate action.
Consumers and healthcare providers should stop using the recalled testosterone pellets immediately. For guidance, contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or consult your healthcare provider. Notifications have been sent via letter.
For questions about this recall, consumers can contact F.H. INVESTMENTS, Inc. at [Insert Phone Number] or visit their website at [Insert Website].
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.